Because TNO155 has been shown to effectively reduce drug-induced feedback activation in KRAS-G12C–mutated lung and colorectal cancer cells (42), we tested combination drug treatments on LAN-6 neuroblastoma xenografts, which harbor both ALK-D1091N and KRAS-G12C mutations. Here, KRAS is linked to neuroblastoma.